Log in

NASDAQ:WHRT - WorldHeart Stock Price, Forecast & News

Today's Range N/A
50-Day Range N/A
52-Week Range N/A
Average VolumeN/A
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
World Heart Corporation (WorldHeart) is engaged in the development and sale of ventricular assist devices (VADs), particularly the Levacor Rotary VAD (Levacor VAD or Levacor). VADs are mechanical assist devices that supplement the circulatory function of the heart by re-routing blood flow through a mechanical pump allowing for the restoration of normal blood circulation. VADs are used for treatment of patients with severe heart failure, including patients whose hearts are irreversibly damaged and cannot be treated effectively by medical or surgical means other than transplant. Bridge-to-Transplant therapy (BTT) therapy involves implanting a VAD in a transplant-eligible patient to maintain or improve the patient's health until a donor heart becomes available. In August 2012, HeartWare International, Inc. acquired WorldHeart.

Industry, Sector and Symbol

Industry N/A
Current SymbolNASDAQ:WHRT



Sales & Book Value

Annual SalesN/A



Next Earnings DateN/A
OptionableNot Optionable

Receive WHRT News and Ratings via Email

Sign-up to receive the latest news and ratings for WHRT and its competitors with MarketBeat's FREE daily newsletter.

WorldHeart (NASDAQ:WHRT) Frequently Asked Questions

What is WorldHeart's stock symbol?

WorldHeart trades on the NASDAQ under the ticker symbol "WHRT."

Has WorldHeart been receiving favorable news coverage?

Media coverage about WHRT stock has trended somewhat negative this week, according to InfoTrie Sentiment. The research firm identifies positive and negative press coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. WorldHeart earned a daily sentiment score of -1.0 on InfoTrie's scale. They also gave media coverage about the healthcare company a news buzz of 10.0 out of 10, indicating that recent press coverage is extremely likely to have an impact on the company's share price in the near term. View News Stories for WorldHeart.

Who are WorldHeart's key executives?

WorldHeart's management team includes the folowing people:
  • Michael Sumner Estes Ph.D., Independent Chairman of the Board (Age 69)
  • Morgan R. Brown CPA, Interim Principal Executive Officer, Chief Financial Officer, Executive Vice President, Secretary (Age 47)
  • John Campbell Woodard Ph.D., Senior Vice President - Scientific Affairs (Age 56)
  • Jeani C. Delagardelle, Independent Director
  • William C. Garriock, Independent Director (Age 74)
  • Anders D. Hove M.D., Independent Director (Age 50)
  • Eugene B. Jones, Independent Director (Age 64)
  • Austin W. Marxe, Independent Director (Age 71)

How do I buy shares of WorldHeart?

Shares of WHRT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is WorldHeart's official website?

The official website for WorldHeart is http://www.worldheart.com/.

How can I contact WorldHeart?

WorldHeart's mailing address is 500 Old Connecticut Path, Ma, SALT LAKE CITY, UT 01701, United States. The healthcare company can be reached via phone at +1-508-7390864.

MarketBeat Community Rating for WorldHeart (NASDAQ WHRT)

Community Ranking:  2.5 out of 5 (star star half star)
Outperform Votes:  52 (Vote Outperform)
Underperform Votes:  52 (Vote Underperform)
Total Votes:  104
MarketBeat's community ratings are surveys of what our community members think about WorldHeart and other stocks. Vote "Outperform" if you believe WHRT will outperform the S&P 500 over the long term. Vote "Underperform" if you believe WHRT will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 12/9/2019 by MarketBeat.com Staff

Featured Article: Leveraged Buyout (LBO)

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel